The Founder

N. Claude Cohen - Chairman & CEO

Dr. Cohen obtained his Ph.D. in Organic Chemistry from the University of Paris (France). He immediately joined Roussel-Uclaf (now Sanofi-Aventis) in Paris where he was Head of Department of Theoretical Medicinal Chemistry and led his team in a number of cardiovascular drug discovery programs.

Dr. Cohen developed an array of methods for three-dimensional drug design that were applied to discovery projects in therapeutic areas such as CNS, CVS, Infection & Immunity and Oncology.

Later, he joined Ciba-Geigy in Switzerland (now Novartis) as Head of Molecular Modeling and Drug Design. His group successfully integrated the modern rational drug design perspective into the company's research projects and consequently, together with his coworkers, Dr. Cohen contributed to the discovery of several drugs including Valsartan (Diovan), which grossed $5 billion in 2008 and Aliskiren (Tekturna/Rasilez) a Renin inhibitor that was commercialized in 2007. As a result of his contribution to the development of the methods and techniques used today in drug discovery, Dr. Cohen is considered by his peers to be one of the pioneers of rational drug design.

In July 2009, Claude was recognized as an ACS Hero of Chemistry together with his other team members from Novartis, for their discovery and development of Aliskiren, the first-in-its class renin inhibitor.